Review of Opioid Pharmacogenetics and Considerations for Pain Management

被引:118
作者
Obeng, Aniwaa Owusu [1 ,2 ,3 ]
Hamadeh, Issam [4 ]
Smith, Michael [5 ]
机构
[1] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA
[2] Mt Sinai Hosp, Dept Pharm, New York, NY 10029 USA
[3] Icahn Sch Med Mt Sinai, Dept Med, Div Gen Internal Med, New York, NY 10029 USA
[4] Levine Canc Inst, Charlotte, NC USA
[5] Univ Michigan, Coll Pharm, 428 Church St, Ann Arbor, MI 48109 USA
来源
PHARMACOTHERAPY | 2017年 / 37卷 / 09期
关键词
opioids; pharmacogenetics; efficacy; toxicity; safety; personalized pain management; personalized dosing; SINGLE-NUCLEOTIDE POLYMORPHISM; RECEPTOR GENE; CANCER PAIN; MORPHINE CONSUMPTION; CYTOCHROME-P450; 2D6; CODEINE THERAPY; CYP2D6; OPRM1; A118G; REQUIREMENTS;
D O I
10.1002/phar.1986
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Opioid analgesics are the standards of care for the treatment of moderate to severe nociceptive pain, particularly in the setting of cancer and surgery. Their analgesic properties mainly emanate from stimulation of the receptors, which are encoded by the OPRM1 gene. Hepatic metabolism represents the major route of elimination, which, for some opioids, namely codeine and tramadol, is necessary for their bioactivation into more potent analgesics. The highly polymorphic nature of the genes coding for phase I and phase II enzymes (pharmacokinetics genes) that are involved in the metabolism and bioactivation of opioids suggests a potential interindividual variation in their disposition and, most likely, response. In fact, such an association has been substantiated in several pharmacokinetic studies described in this review, in which drug exposure and/or metabolism differed significantly based on the presence of polymorphisms in these pharmacokinetics genes. Furthermore, in some studies, the observed variability in drug exposure translated into differences in the incidence of opioid-related adverse effects, particularly nausea, vomiting, constipation, and respiratory depression. Although the influence of polymorphisms in pharmacokinetics genes, as well as pharmacodynamics genes (OPRM1 and COMT) on response to opioids has been a subject of intense research, the results have been somehow conflicting, with some evidence insinuating for a potential role for OPRM1. The Clinical Pharmacogenetics Implementation Consortium guidelines provide CYP2D6-guided therapeutic recommendations to individualize treatment with tramadol and codeine. However, implementation guidelines for other opioids, which are more commonly used in real-world settings for pain management, are currently lacking. Hence, further studies are warranted to bridge this gap in our knowledge base and ultimately ascertain the role of pharmacogenetic markers as predictors of response to opioid analgesics.
引用
收藏
页码:1105 / 1121
页数:17
相关论文
共 67 条
[1]   Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study [J].
Andreassen, Trine Naalsund ;
Eftedal, Ingrid ;
Klepstad, Pal ;
Davies, Andrew ;
Bjordal, Kristin ;
Lundstrom, Staffan ;
Kaasa, Stein ;
Dale, Ola .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (01) :55-64
[2]  
[Anonymous], FDA DRUG SAF COMM SA
[3]   Postoperative pain experience: Results from a national survey suggest postoperative pain continues to be undermanaged [J].
Apfelbaum, JL ;
Chen, C ;
Mehta, SS ;
Gan, TJ .
ANESTHESIA AND ANALGESIA, 2003, 97 (02) :534-540
[4]   The pharmacogenetics of codeine pain relief in the postpartum period [J].
Baber, M. ;
Chaudhry, S. ;
Kelly, L. ;
Ross, C. ;
Carleton, B. ;
Berger, H. ;
Koren, G. .
PHARMACOGENOMICS JOURNAL, 2015, 15 (05) :430-435
[5]   Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter:: A balanced polymorphism for regulation of bilirubin metabolism? [J].
Beutler, E ;
Gelbart, T ;
Demina, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) :8170-8174
[6]  
Boswell MV, 2013, PAIN PHYSICIAN, V16, pE227
[7]   The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis [J].
Brousseau, David C. ;
McCarver, D. Gail ;
Drendel, Amy L. ;
Divakaran, Karthika ;
Panepinto, Julie A. .
JOURNAL OF PEDIATRICS, 2007, 150 (06) :623-626
[8]   How Much Oxycodone Is Needed for Adequate Analgesia After Breast Cancer Surgery: Effect of the OPRM1 118A>G Polymorphism [J].
Cajanus, Kristiina ;
Kaunisto, Mari A. ;
Tallgren, Minna ;
Jokela, Ritva ;
Kalso, Eija .
JOURNAL OF PAIN, 2014, 15 (12) :1248-1256
[9]   Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief [J].
Campa, D. ;
Gioia, A. ;
Tomei, A. ;
Poli, P. ;
Barale, R. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (04) :559-566
[10]   Association of μ-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty [J].
Chou, W. -Y. ;
Yang, L. -C. ;
Lu, H. -F. ;
Ko, J. -Y. ;
Wang, C. -H. ;
Lin, S. -H. ;
Lee, T. -H. ;
Concejero, A. ;
Hsu, C. -J. .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2006, 50 (07) :787-792